These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

155 related articles for article (PubMed ID: 24492031)

  • 1. [Recent issues and prospects of the treatment of aplastic anemia].
    Nakao S
    Rinsho Ketsueki; 2014 Jan; 55(1):5-11. PubMed ID: 24492031
    [No Abstract]   [Full Text] [Related]  

  • 2. [Recent progress in the management of aplastic anemia].
    Nakao S
    Rinsho Ketsueki; 2014 Oct; 55(10):1762-8. PubMed ID: 25297738
    [No Abstract]   [Full Text] [Related]  

  • 3. Eltrombopag combined with cyclosporine may have an effect on very severe aplastic anemia.
    Cheng H; Wang X; Zhou D; Cao J; Larochelle A; Xu KL
    Ann Hematol; 2019 Aug; 98(8):2009-2011. PubMed ID: 30891613
    [No Abstract]   [Full Text] [Related]  

  • 4. Are eltrombopag plasma and skin hyperpigmentation related? The eyes have it.
    Rodgers GM; Kurtti AL; Gilreath JA
    Am J Hematol; 2019 Mar; 94(3):394-395. PubMed ID: 30033660
    [No Abstract]   [Full Text] [Related]  

  • 5. Longitudinal evaluation of eltrombopag in paediatric acquired severe aplastic anaemia.
    Filippidou M; Avgerinou G; Tsipou H; Tourkantoni N; Katsibardi K; Vlachou A; Roka K; Solomou E; Kattamis A
    Br J Haematol; 2020 Aug; 190(3):e157-e159. PubMed ID: 32529633
    [No Abstract]   [Full Text] [Related]  

  • 6. Eltrombopag preferentially expands haematopoietic multipotent progenitors in human aplastic anaemia.
    Quintino de Oliveira B; Catto LFB; Santana BAA; Tellechea MF; Scheucher PS; Scheinberg P; Calado RT
    Br J Haematol; 2021 Apr; 193(2):410-414. PubMed ID: 33216370
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Management of idiopathic thrombocytopenic purpura (primary immune thrombocytopenia, ITP)].
    Kashiwagi H; Tomiyama Y
    Rinsho Ketsueki; 2014 Oct; 55(10):2087-94. PubMed ID: 25297775
    [No Abstract]   [Full Text] [Related]  

  • 8. Effect of cyclosporine coadministration on the pharmacokinetics of eltrombopag in healthy volunteers.
    Aslanis V; Zhang J; Lomeli B; Grosch K; Ouatas T
    Cancer Chemother Pharmacol; 2018 Nov; 82(5):847-855. PubMed ID: 30171280
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Eltrombopag Added to Standard Immunosuppression for Aplastic Anemia.
    Townsley DM; Scheinberg P; Winkler T; Desmond R; Dumitriu B; Rios O; Weinstein B; Valdez J; Lotter J; Feng X; Desierto M; Leuva H; Bevans M; Wu C; Larochelle A; Calvo KR; Dunbar CE; Young NS
    N Engl J Med; 2017 Apr; 376(16):1540-1550. PubMed ID: 28423296
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Persistent elevation of plasma thrombopoietin levels after treatment in severe aplastic anemia.
    Zhao X; Feng X; Wu Z; Winkler T; Desmond R; Olnes M; Dumitriu B; Townsley DM; Dunbar CE; Young NS
    Exp Hematol; 2018 Feb; 58():39-43. PubMed ID: 28941711
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Thrombopoietin receptor agonist arouses new hope].
    Häckel A
    MMW Fortschr Med; 2016 Apr; 158(7):73. PubMed ID: 27071600
    [No Abstract]   [Full Text] [Related]  

  • 12. Eltrombopag as initial monotherapy for severe aplastic anemia-a case report.
    Rodgers GM; Gilreath JA
    Ann Hematol; 2018 Aug; 97(8):1517-1518. PubMed ID: 29560523
    [No Abstract]   [Full Text] [Related]  

  • 13. Addition of eltrombopag to immunosuppressive therapy in patients with newly diagnosed aplastic anemia.
    Assi R; Garcia-Manero G; Ravandi F; Borthakur G; Daver NG; Jabbour E; Burger J; Estrov Z; Dinardo CD; Alvarado Y; Hendrickson S; Ferrajoli A; Wierda W; Cortes J; Kantarjian H; Kadia TM
    Cancer; 2018 Nov; 124(21):4192-4201. PubMed ID: 30307606
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Iron mobilization in a real life cohort of aplastic anemia patients treated with eltrombopag.
    Fattizzo B; Cavallaro F; Milesi G; Barcellini W
    Am J Hematol; 2019 Sep; 94(9):E237-E239. PubMed ID: 31172568
    [No Abstract]   [Full Text] [Related]  

  • 15. An Eltrombopag Red (Plasma) Alert.
    Al-Samkari H; Goodarzi K
    Acta Haematol; 2021; 144(2):227-228. PubMed ID: 32702690
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Eltrombopag for the treatment of aplastic anemia: current perspectives.
    Lum SH; Grainger JD
    Drug Des Devel Ther; 2016; 10():2833-2843. PubMed ID: 27695288
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [The use of allogeneic bone marrow transplantation and immunosuppressive therapy in the treatment of patients with acquired aplastic anemia].
    Ganapiev AA; Golubovskaia IK; Zalialov IuR; Estrina MA; Afanas'ev BV
    Ter Arkh; 2010; 82(7):48-52. PubMed ID: 20853609
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Clinical and morphological predictors of outcome in older aplastic anemia patients treated with eltrombopag.
    Fattizzo B; Kulasekararaj AG; Hill A; Benson-Quarm N; Griffin M; Munir T; Arnold L; Riley K; Ireland R; De Lavallade H; Potter V; Consonni D; Hillmen P; Mufti GJ; Barcellini W; Marsh JCW
    Haematologica; 2019 Nov; 104(11):e494-e496. PubMed ID: 30890599
    [No Abstract]   [Full Text] [Related]  

  • 19. Aplastic Anemia.
    Young NS
    N Engl J Med; 2018 Oct; 379(17):1643-1656. PubMed ID: 30354958
    [No Abstract]   [Full Text] [Related]  

  • 20. High-dose cyclophosphamide in aplastic anaemia.
    Brodsky RA; Jones RJ
    Lancet; 2001 Apr; 357(9262):1128-9. PubMed ID: 11303606
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 8.